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Abstract
Background: Recent reports have observed that individuals with serrated polyps, some of whom meet the clinical
diagnostic criteria for Serrated Polyposis Syndrome (SPS), are among those who carry germline mutations in genes
associated with polyposis syndromes including; (1) genes known to underlie hamartomatous polyposes (SMAD4, BMPR1A,
and PTEN), (2) MUTYH-associated polyposis and (3) GREM1 in Hereditary Mixed Polyposis Syndrome (HMPS). The aim of this
study was to characterise individuals fulfilling the current WHO criteria for SPS for germline mutations in these polyposis-
associated genes.
Methods: A total of 65 individuals with SPS (fulfilling WHO criteria 1 or 3), were recruited to the Genetics of Serrated
Neoplasia study between 2000 and 2012, through multiple Genetics or Family Cancer Clinics within Australia, or from the
New Zealand Familial Gastrointestinal Cancer Service. Individuals with SPS were tested for coding mutations and large
deletions in the PTEN, SMAD4, and BMPR1A genes, for the MUTYH variants in exons 7 (Y179C) and 13 (G396D), and for the
duplication upstream of GREM1.
Results: We found no variants that were likely to be deleterious germline mutations in the SPS cases in the PTEN, SMAD4,
and BMPR1A genes. A novel variant in intron 2 (c.164+223T.C) of PTEN was identified in one individual and was predicted
by in silico analysis to have no functional consequences. One further individual with SPS was found to be mono-allelic for
the MUTYH G396D mutation. No individuals carried the recently reported duplication within GREM1.
Conclusions: Genes involved in the gastrointestinal hamartomatous polyposis, Hereditary Mixed Polyposis Syndrome and
MUTYH-associated polyposis syndromes are not commonly altered in individuals with SPS.
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Introduction
Serrated Polyposis Syndrome (SPS), previously known as
hyperplastic polyposis syndrome, is a colorectal polyposis condi-
tion of unknown genetic basis associated with an increased risk of
developing colorectal cancer (CRC) in both the affected individual
and their first- and second-degree relatives [1]. CRC has been
detected in 25–50% of individuals with SPS, most often identified
at time of cancer diagnosis [2,3,4,5,6,7,8]. SPS was first described
in the 1970s [9], however, it has only recently been recognised as a
condition with a potential genetic basis, with a reported five-fold
increase in risk of CRC [1,10], and a 3.5-fold increase in risk of
pancreatic cancer for first-degree relatives of individuals with SPS
[1]. SPS is characterised by the occurrence of multiple serrated
PLOS ONE | www.plosone.org 1 June 2013 | Volume 8 | Issue 6 | e66705
polyps in the colon and/or rectum, including hyperplastic polyps
and sessile serrated adenomas. In addition, conventional adeno-
mas of the large intestine are also identified in up to 80% of
individuals with SPS [6,11,12] and have been found to be more
frequently present in CRC-affected individuals with SPS. SPS is
currently diagnosed by the following criteria as defined by the
WHO in 2010 [13]:
(1) at least 5 serrated polyps proximal to the sigmoid colon, with 2
or more of these being .10 mm; OR
(2) any number of serrated polyps proximal to the sigmoid colon
in an individual who has a first-degree relative with serrated
polyposis; OR
(3) .20 serrated polyps of any size but distributed throughout the
colon.
Other rare colonic polyposis syndromes for which the genetic
basis is known include Cowden syndrome (mutations in PTEN),
juvenile polyposis (mutations in SMAD4 or BMPR1A), hereditary
mixed polyposis syndrome (mutation in GREM1), and MUTYH-
associated polyposis (biallelic mutations in MUTYH). Cowden
syndrome is part of a disease complex known as the PTEN
hamartoma tumour syndrome (PHTS) and is associated with
macrocephaly, malignant and benign tumours of the endometri-
um, thyroid and breast [14], and hamartomatous polyposis of the
gastrointestinal tract [15]. Other polyp sub-types have also been
reported in individuals with germline PTEN mutations. In a recent
article by Heald et al. [16], 40% of the individuals who underwent
colonoscopy were found to have serrated (hyperplastic) polyps.
Among those individuals with serrated polyps, 60% met the
current WHO clinical criteria for SPS [13].
Multiple serrated polyps and adenomas have also been
described in individuals with BMPR1A [17], biallelic MUTYH
mutations [18] and SMAD4mutation [19], genes that are normally
associated with juvenile or adenomatous polyposes. In addition,
mutations in GREM1, which plays a role in the inhibition of BMP
signalling, have been reported to underlie Hereditary Mixed
Polyposis Syndrome (HMPS), a rare condition characterised by
the occurrence of conventional adenomas, atypical hamartoma-
tous polyps, serrated polyps and frequent colorectal carcinoma
[20,21]. Given SPS is observed in mutation carriers associated
with these polyposes syndromes, we hypothesised that these genes
may be altered in individuals with SPS and may account, at least
partially, for the development of this condition. The aim of this
study was to determine the frequency of germline mutations in the
PTEN, SMAD4, BMPR1A, MUTYH and GREM1 genes in a large
series of individuals with SPS.
Methods
Ethics Statement
Written informed consent was obtained from all study
participants and the study protocol was approved by the Human
Research Ethics Committee of the Queensland Institute of
Medical Research under protocol P912.
Study Participants
A total of 65 individuals with SPS, meeting WHO criteria 1 or 3
[13] and with DNA available for genetic testing, recruited from
multiple Genetics or Family Cancer Clinics within Australia
(AUS), or from the New Zealand Familial Gastrointestinal Cancer
Service, Auckland, New Zealand (NZL), between 2000 and 2012
to the Genetics of Serrated Neoplasia (GSN) study [1,11,12] were
selected for this study. All included individuals with SPS were
recruited regardless of a family history of polyps or cancer. All SPS
cases in this study were Caucasian. Individuals who fulfilled WHO
criteria 2 [13] were not included in this study of unrelated SPS
cases as, by definition, they were likely to be relatives of the 65 SPS
probands.
Gene Testing
Individuals with SPS were screened for mutations in the coding
regions and directly flanking introns in the PTEN, SMAD4 and
BMPR1A genes as follows. Standard PCR was performed to
amplify 50 ng of buffy coat derived DNA across exons 1–9 of
PTEN (NM_000314.4), exons 2–12 of SMAD4 (NM_005359.5),
and exons 3–13 of BMPR1A (NM_004329.2) using GoTaq
mastermix (Promega, Madison, WI), (primer sequences available
on request). PCR products underwent clean-up using Multi-screen
HTS PCR plates (Millipore, Billerica, MA). Sequencing was
performed in a single direction using ABI BigDye v3.1, and
subsequently treated with ABI Xterminator reagent (Life Tech-
nologies, Carlsbad, CA). Sequencing reactions were run on an ABI
3100 genetic analyser, and annotated using DNA Star Lasergene 8
software (DNAstar, Madison, WI). To identify large rearrange-
ments (deletions or duplications) in PTEN, SMAD4 and BMPR1A,
multiplex ligation-dependent probe amplification (MLPA) was
performed using the JPS MLPA kit (P158; MRC Holland).
The common European variants of MUTYH, c.536A.G
p.Tyr179Cys (Y179C) in exon 7 and c.1187G.A p.Gly396Asp
(G396D) in exon 13, were tested using a high resolution melt curve
(HRM) analysis assay. Briefly, 10 ng of DNA was amplified in a
15 ml reaction, containing 300 nM of each primer (1F-59-
TCCTACCCACAGGAGGTGAA-39 and 2R-59-
CCTGCCATCCCCTTACCTT-39 for the Y197C variant or
1F-59- GGGCAGTGGCATGAGTAAC-39 and 2R-59- GACGG-
GAACTCCCACAGTC-39 for the G396D variant), 1U of
platinum Taq, 1.5 mM of MgCl2 (Life Technologies, Carlsbad,
CA), 200 nM of dNTPs and 1 mM of SYTO9 dye (Life
Technologies, Carlsbad, CA), under PCR cycling conditions of
denaturation at 95uC for 2 mins followed by 40 cycles of 95uC for
15 secs, 62uC (Y179C) or 66uC (G396D) for 15 secs and 72uC for
15 secs. A final high resolution melting analysis was performed by
increasing 0.25uC temperature steps from 80uC until complete
denaturation at 95uC. Melting curves for individual samples were
compared to reference samples for each of the three genotypes for
either the Y179C or G396D variants that had been previously
confirmed by Sanger sequencing.
A heterozygous single-copy duplication of approximately 40 kb
on chromosome 15q13.3 (30,752,231–30,792,051) was recently
identified in individuals with HMPS [20]. The duplication resulted
in an insertion of a 30-bp sequence of unknown origin and
extended from intron 2 of SCG5 to a site just upstream of the
GREM1 CpG island. A PCR product spanning the duplication
boundary produced a unique 190 bp product in carriers with a
separate PCR product of 435 bp upstream of GREM1 used as a
control sequence for amplification. Products were amplified in a
15 ul reaction using GoTaq mastermix (Promega, Madison, WI)
and 300 nM of each primer 1F-59-
GGGCATCTTCTGGTCTCT-39 and 2R-59- AGTGA-
GACCTGGGGAAAG-39 for the 190 bp duplication product or
1F-59- GGGCATCTTCTGGTCTCT-39 and 2R-59-
CGACCGGGTCTTATGTATC-39 for the 435 bp control prod-
uct. PCR cycling conditions included a denaturation step at 95uC
for 2 mins followed by 40 cycles of 95uC for 15 secs, 60uC for
15 secs and 72uC for 15 secs. All products were separated on a 2%
agarose gel alongside a positive control for the duplication.
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Results
The baseline characteristics of the 65 individuals with SPS are
shown in Table 1. Briefly, the average age at diagnosis of SPS was
51.5 yrs with standard deviation (SD) of 15.3 yrs with a female
predominance (60%). The average polyp count was 31.7
(SD=23.5) with 83.1% of the individuals with SPS having .20
serrated polyps of any size throughout the colon (fulfilling WHO
criteria 3). A personal history of CRC or having a first-degree
relative with CRC was reported in 32.3% and 23%, respectively.
No deleterious germline mutations in PTEN were identified in
the 65 individuals with SPS. The c.80–96A.G (rs1903858)
polymorphism was identified in one individual. In a single SPS
individual, we also identified a novel variant in intron 2
(c.164+223T.C) of PTEN, which was predicted by in silico
analysis (NNSPLICE 0.9 at http://www.fruitfly.org/seq_tools/
splice.html) to have no functional consequences. In addition, no
deleterious germline mutations in BMPR1A or SMAD4 were
identified in the 65 SPS individuals. Similarly, no large deletions or
duplications in PTEN, BMPR1A or SMAD4 were observed.
We found no biallelic mutation carriers for the MUTYH
variants c.536A.G p.Tyr179Cys (Y179C) in exon 7 and
c.1187G.A p.Gly396Asp (G396D) in exon 13, after screening
with a novel high resolution melt curve (HRM) analysis assay.
However, a single SPS case was shown to be a monoallelic carrier
of the G396D variant. The recently described duplication
upstream of GREM1 was screened for in all sixty-five SPS
individuals with no carriers being identified.
Discussion
SPS is a clinically defined condition by arbitrary criteria for
which a genetic cause is yet to be identified. The observation that
multiple colonic serrated polyps, including in individuals meeting
the clinical criteria for SPS, has been observed among mutations
carriers of genes causing other rare polyposes syndromes (PTEN
[16], BMPR1A [17], MUTYH [18], SMAD4 and GREM1) raises
the question that these genes should be tested for in individuals
with SPS. In this study of 65 individuals with well characterised
SPS, we did not observe any deleterious mutations in the PTEN,
BMPR1A or SMAD4 genes or any biallelic carriers of the most
common MUTYH mutations, Y179C and G396D, and no
evidence of the duplication upstream of the GREM1 gene.
Although we did not identify mutations within these genes, other
transcriptional silencing or protein disrupting mechanisms such as
intronic mutations or germline gene promoter methylation
(epimutations), as can occur in the mismatch repair genes
[22,23], cannot be excluded.
The polyp burden for individuals with Cowden syndrome is
relatively high, with greater than 50 polyps present in over half of
these individuals [24]. Though the majority of polyps observed in
individuals with germline mutations in PTEN are hamartomas,
ganglioneuromas and inflammatory polyps, one recent study
observed an unexpectedly high incidence of individuals (24%) with
co-existent serrated polyps that met the clinical criteria for SPS
[16]. A previous report from Sweet et al. [25] found two PTEN
mutation carriers within 23 individuals with co-existent SPS (9%).
In the report by Heald et al. [16] the authors state that the majority
of individuals with PTEN mutation had macrocephaly, as did both
individuals with SPS reported by Sweet et al. [25]. In contrast, we
observed no PTEN mutations in our 65 individuals with SPS.
Therefore, in the absence of any other Cowden-like phenotypic
features, macrocephaly could potentially be used to guide PTEN
mutation screening in individuals presenting with SPS.
Multiple serrated polyps are also seen in MUTYH-associated
polyposis, a disorder with a variety of phenotypes ranging from no
gastrointestinal polyps through adenomatous polyps to mixed
polyposis phenotypes [26]. In one study, 18% of biallelic mutation
carriers met the clinical criteria for SPS [18], further supporting
the concept of phenotypic variability due to differing genetic
backgrounds. We have previously shown that, similarly to PTEN,
although SPS is observed among MUTYH mutation carriers,
MUTYH mutations are rare amongst individuals with SPS [27].
Therefore, the observations from these previous studies and the
current study (only a single monoallelic MUTYH mutation carrier
identified in 65 SPS individuals) further support the concept that
the common MUTYH mutations in Europeans do not underlie the
majority of SPS. However, this does not exclude the possibility
that other variants within the MUTYH gene may be associated
with risk of SPS.
In addition, individuals with germline mutations in the
BMPR1A and SMAD4 genes may also express variable phenotypes,
some of which include multiple serrated polyps of the large
intestine. Case reports have shown that in BMPR1A families with
polyposis phenotypes, polyps of both serrated and adenomatous
lineages are present [28], Juvenile polyps dominate the gastroin-
testinal phenotype in SMAD4 mutation carriers, however, a
deleterious frameshift mutation in SMAD4 has been described in
a case of juvenile polyposis previously classified as SPS, where
multiple serrated polyps were also present [19]. Therefore, the
possibility exists that germline mutations in these polyposis-
associated genes may be interacting with a more common genetic
Table 1. Characteristics of SPS cases in the study.
N (%)
Sex female 39 (60%)
male 26 (40%)








WHO criteria? 1 6 (9.2%)
3 54 (83.1%)
Inconclusive‘ 5 (7.7%)






*minimum number of polyps observed, polyp count may be a cumulative
count.
?The frequency of individuals with SPS that meet WHO criteria 1 or 3, where
individuals that met WHO criteria 2 only weren’t included.
‘WHO criteria could not be determined as polyp count listed as ‘‘multiple’’ but
.5.
doi:10.1371/journal.pone.0066705.t001
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background present in the population to produce a phenotype of
SPS in a subset of individuals.
Hereditary Mixed Polyposis Syndrome (HMPS) is characterised
by the development of polyposis with mixed polyp morphologies
including conventional adenomas, serrated polyps, atypical
juvenile polyps, and an increased risk of CRC [29]. The recently
reported 40 kb duplication upstream of the GREM1 gene that
results in the increased expression of GREM1 mRNA has been
demonstrated to underlie HMPS, however, the families that have
thus far been shown to carry this mutation have been of Ashkenazi
Jewish descent [20]. In contrast, current evidence suggests that
SPS [6], and serrated polyps in general [30], are significantly more
common in northern Europeans of primarily Anglo-Celtic descent,
therefore, the absence of the duplication upstream of GREM1 in
SPS cases in this study is not surprising. Furthermore, in this study,
we tested only for the 40 kb duplication associated with HMPS
and therefore, the possibility exists that other genetic variants
within the GREM1 locus may underlie SPS. Additional evidence to
support this region in colonic neoplasia predisposition resides with
SNPs within the GREM1 locus (rs16969681 and rs11632715) that
were associated with CRC risk from genome-wide association
studies [31] and the description of a whole-gene duplication of
GREM1 described in a single CRC-affected individual [32].
SPS has recently gained recognition as an inferred genetic
disorder associated with an increased risk for CRC in both
individuals [3], and a five-fold increased risk for CRC in first-
degree relatives [1,10]. It is not known whether SPS individuals
reported in the polyposis-associated gene mutation carriers have
the same increased risk of CRC. The suggestion of Heald et al [16]
that this phenotype in individuals with PTEN mutation be
considered as a marker for increased CRC risk is an important
one. Though rare reports of SPS in individuals with germline
PTEN mutation resulting directly from PTEN mutation itself
cannot be ruled out, it is also possible that such individuals may be
segregating more than one disorder. This concept has been
previously demonstrated in two kindreds segregating Lynch
syndrome and a predisposition for serrated neoplasia [33], and
therefore, in families presenting with serrated polyps and with a
mutation in one of these polyposis-associated genes, CRC
surveillance may be warranted in individual relatives who do not
carry the family mutation.
In conclusion, we found no germline deleterious mutation in
PTEN, BMPR1A, or SMAD4 genes, no biallelic carriers of the
common MUTYH mutations and no evidence of the duplication
involving GREM1, in our series of 65 well characterised SPS
individuals. The observation that mutations in the PTEN, SMAD4,
BMPR1A, MUTYH and GREM1 genes are rarely observed in
individuals with SPS may help inform decision making for future
genetic screening.
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